CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
HOUSTON, Nov. 26, 2019 -- (Healthcare Sales & Marketing Network) -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, entered into a sublicense agr... Biopharmaceuticals, Oncology, Licensing CNS Pharmaceuticals, WPD Pharmaceuticals, Berubicin, glioblastoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Marketing | Neurology | Pharmaceuticals